In the past week, NBIX stock has gone up by 5.38%, with a monthly decline of -1.16% and a quarterly plunge of -18.69%. The volatility ratio for the week is 2.11%, and the volatility levels for the last 30 days are 1.99% for Neurocrine Biosciences, Inc. The simple moving average for the past 20 days is 2.95% for NBIX’s stock, with a -12.58% simple moving average for the past 200 days.
Is It Worth Investing in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Right Now?
The price-to-earnings ratio for Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is 35.79x, which is above its average ratio. Moreover, the 36-month beta value for NBIX is 0.36. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NBIX is 98.78M and currently, short sellers hold a 2.48% of that float. On October 18, 2024, NBIX’s average trading volume was 919.05K shares.
NBIX) stock’s latest price update
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)’s stock price has soared by 0.09 in relation to previous closing price of 118.35. Nevertheless, the company has seen a gain of 5.38% in its stock price over the last five trading days. seekingalpha.com reported 2024-10-10 that Neurocrine Biosciences’ Ingrezza has grown into a multibillion-dollar drug, but the company’s stock has underperformed the S&P 500 since 2019. Neurocrine’s NBI-1117568 demonstrated encouraging Phase 2 schizophrenia data, though dose inconsistencies raised questions about efficacy. The stock’s recent decline is an overreaction, presenting a buying opportunity given its CNS pipeline and Ingrezza’s ongoing growth.
Analysts’ Opinion of NBIX
Many brokerage firms have already submitted their reports for NBIX stocks, with Raymond James repeating the rating for NBIX by listing it as a “Outperform.” The predicted price for NBIX in the upcoming period, according to Raymond James is $155 based on the research report published on October 10, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see NBIX reach a price target of $159, previously predicting the price at $131. The rating they have provided for NBIX stocks is “Overweight” according to the report published on August 29th, 2024.
Wells Fargo gave a rating of “Overweight” to NBIX, setting the target price at $170 in the report published on April 24th of the current year.
NBIX Trading at -6.72% from the 50-Day Moving Average
After a stumble in the market that brought NBIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.02% of loss for the given period.
Volatility was left at 1.99%, however, over the last 30 days, the volatility rate increased by 2.11%, as shares sank -1.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.81% lower at present.
During the last 5 trading sessions, NBIX rose by +5.38%, which changed the moving average for the period of 200-days by -10.07% in comparison to the 20-day moving average, which settled at $115.06. In addition, Neurocrine Biosciences, Inc. saw -10.09% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NBIX starting from Boyer David W., who sale 3,461 shares at the price of $121.88 back on Sep 13 ’24. After this action, Boyer David W. now owns 1,672 shares of Neurocrine Biosciences, Inc., valued at $421,828 using the latest closing price.
DAVID WARREN BOYER, the Officer of Neurocrine Biosciences, Inc., proposed sale 4,756 shares at $121.28 during a trade that took place back on Sep 13 ’24, which means that DAVID WARREN BOYER is holding shares at $576,808 based on the most recent closing price.
Stock Fundamentals for NBIX
Current profitability levels for the company are sitting at:
- 0.26 for the present operating margin
- 0.98 for the gross margin
The net margin for Neurocrine Biosciences, Inc. stands at 0.16. The total capital return value is set at 0.19. Equity return is now at value 15.55, with 11.46 for asset returns.
Based on Neurocrine Biosciences, Inc. (NBIX), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 1.82. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is 165.06.
Currently, EBITDA for the company is 416.1 million with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of 5.72. The receivables turnover for the company is 4.53for trailing twelve months and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.19.
Conclusion
To wrap up, the performance of Neurocrine Biosciences, Inc. (NBIX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
